Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors

We report a phase I pharmacological study of an oral formulation of CKD‐516, a vascular‐disrupting agent, in patients with refractory solid tumors. Twenty‐seven patients (16 in the dose‐escalation cohort and 11 in the expansion cohort) received a single daily dose (5‐25 mg) of CKD‐516 five days per...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hark Kyun, Kang, Jeong Won, Park, Young‐Whan, Kim, Jung Young, Kim, Minchae, Kim, Soo Jin, Kim, Se‐mi, Ho Ryu, Keun, Yoon, Seonghae, Kim, Yun, Cho, Joo‐Youn, Lee, Keun Seok, Yun, Tak, Kim, Kiwon, Kwak, Mi Hyang, Kim, Tae‐Sung, Chung, Jinsoo, Park, Joong‐Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066534/
https://www.ncbi.nlm.nih.gov/pubmed/32162844
http://dx.doi.org/10.1002/prp2.568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066534/
https://www.ncbi.nlm.nih.gov/pubmed/32162844
http://dx.doi.org/10.1002/prp2.568

Ejemplares similares